Argent Biopharma (ASX:RGT) ROCE % : -1,680.91% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is Argent Biopharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Argent Biopharma's annualized ROCE % for the quarter that ended in Dec. 2023 was -1,680.91%.

Argent Biopharma ROCE % Historical Data

The historical data trend for Argent Biopharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Argent Biopharma ROCE % Chart

Argent Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

ROCE %

Get a 7-Day Free Trial

-15.84

-236.23

-130.64

-141.99

-556.42

Argent Biopharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-72.30	-152.84	-302.43	-12,950.33	-1,680.91

Argent Biopharma ROCE % Calculation

Argent Biopharma's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-20.874	/	( ( (18.558 - 7.707)	+	(9.984 - 13.332) )	/ 2 )
	=	-20.874	/	( (10.851	+	-3.348)	/ 2 )
	=	-20.874	/	3.7515
	=	-556.42 %

Argent Biopharma's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-13.254	/	( ( (9.984 - 13.332)	+	(17.334 - 12.409) )	/ 2 )
	=	-13.254	/	( ( -3.348	+	4.925 )	/ 2 )
	=	-13.254	/	0.7885
	=	-1,680.91 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Argent Biopharma (ASX:RGT) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Argent Biopharma ROCE % Related Terms

Thank you for viewing the detailed overview of Argent Biopharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Argent Biopharma (ASX:RGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Argent Biopharma Ltd (ASX:RGT) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

MGCLF:USA MXC:UK H5O:Germany

Address

295 Rokeby Road, Suite 1, Subiaco, WA, AUS, 6008

Website

https://mgcpharma.co.uk

MGC Pharmaceuticals Ltd is a biopharma company with a Nature to Medicine strategy at the forefront of the emerging phytocannabinoid and plant-derived medicine markets. The company's mission is to build an innovative, global bio-pharma company providing standardized, affordable plant-derived medicines of the highest regulatory compliance for targeted global markets.